Literature DB >> 17666087

Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones.

Andrea M Haqq1, Michael Muehlbauer, Laura P Svetkey, Christopher B Newgard, Jonathan Q Purnell, Steven C Grambow, Michael S Freemark.   

Abstract

OBJECTIVE: Prader-Willi syndrome (PWS) is a genetic syndrome characterized by relative hypoinsulinaemia and normal or increased insulin sensitivity despite profound obesity. We hypothesized that this increased insulin sensitivity is mediated by increased levels of total and high molecular weight adiponectin and associated with changes in levels of satiety hormones. DESIGN, PATIENTS AND MEASUREMENTS: We measured total adiponectin and its isoforms [high molecular weight (HMW), middle molecular weight (MMW) and low molecular weight (LMW) adiponectin] and satiety hormones in 14 children with PWS [median age 11.35 years, body mass index (BMI) Z-score 2.15] and 14 BMI-matched controls (median age 11.97 years, BMI Z-score 2.34).
RESULTS: Despite comparable BMI Z-scores and leptin levels, the PWS children exhibited lower fasting insulin and HOMA-IR (homeostasis model assessment of insulin resistance) scores compared to obese controls. For any given BMI Z-score, the PWS children showed higher concentrations of fasting total and HMW adiponectin and higher HMW/total adiponectin ratios. The HMW/total adioponectin ratio was preserved in children with PWS at high degrees of obesity. In PWS children, fasting plasma total adiponectin, HMW adiponectin and HMW/total adiponectin ratio correlated negatively with age (P < 0.05), HOMA-IR (P < 0.01), BMI Z-score (P < 0.05), insulin (P < 0.01) and leptin (P < 0.05). In addition to higher fasting ghrelin concentrations, the PWS children showed significantly higher fasting levels of total peptide YY (PYY) and gastric inhibitory polypeptide (GIP) compared to obese controls.
CONCLUSIONS: Relative to controls of similar age and BMI Z-score, the PWS children had significantly higher levels of total and HMW adiponectin, and increased ratios of HMW/total adiponectin. These findings may explain in part the heightened insulin sensitivity of PWS children relative to BMI-matched controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666087      PMCID: PMC2605973          DOI: 10.1111/j.1365-2265.2007.02991.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  47 in total

1.  Elevated plasma ghrelin levels in Prader Willi syndrome.

Authors:  David E Cummings; Karine Clement; Jonathan Q Purnell; Christian Vaisse; Karen E Foster; R Scott Frayo; Michael W Schwartz; Arnaud Basdevant; David S Weigle
Journal:  Nat Med       Date:  2002-07       Impact factor: 53.440

2.  Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.

Authors:  W B Zipf
Journal:  Acta Paediatr Suppl       Date:  1999-12

3.  Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes.

Authors:  Mathias Fasshauer; Johannes Klein; Susanne Neumann; Markus Eszlinger; Ralf Paschke
Journal:  Biochem Biophys Res Commun       Date:  2002-01-25       Impact factor: 3.575

4.  Plasma obestatin and ghrelin levels in subjects with Prader-Willi syndrome.

Authors:  Merlin G Butler; Douglas C Bittel
Journal:  Am J Med Genet A       Date:  2007-03-01       Impact factor: 2.802

5.  Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.

Authors:  D A M Festen; A van Toorenenbergen; H J Duivenvoorden; A C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2007-01-30       Impact factor: 5.958

6.  Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency.

Authors:  A Ciresi; M C Amato; A Criscimanna; A Mattina; C Vetro; A Galluzzo; G D'Acquisto; C Giordano
Journal:  Eur J Endocrinol       Date:  2007-03       Impact factor: 6.664

Review 7.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.

Authors:  Anders H Berg; Terry P Combs; Philipp E Scherer
Journal:  Trends Endocrinol Metab       Date:  2002-03       Impact factor: 12.015

Review 8.  Adipose tissue, inflammation, and cardiovascular disease.

Authors:  Anders H Berg; Philipp E Scherer
Journal:  Circ Res       Date:  2005-05-13       Impact factor: 17.367

9.  Adrenarche in Prader-Willi syndrome appears not related to insulin sensitivity and serum adiponectin.

Authors:  Nancy Unanue; Rodrigo Bazaes; Germán Iñiguez; Fanny Cortés; Alejandra Avila; Verónica Mericq
Journal:  Horm Res       Date:  2006-11-02

10.  Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution.

Authors:  A P Goldstone; E L Thomas; A E Brynes; J D Bell; G Frost; N Saeed; J V Hajnal; J K Howard; A Holland; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

View more
  21 in total

1.  Lower brain-derived neurotrophic factor in patients with prader-willi syndrome compared to obese and lean control subjects.

Authors:  Joan C Han; Michael J Muehlbauer; Huaxia N Cui; Christopher B Newgard; Andrea M Haqq
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

Review 2.  Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.

Authors:  Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

3.  Metabolic profiling in Prader-Willi syndrome and nonsyndromic obesity: sex differences and the role of growth hormone.

Authors:  Krystal A Irizarry; James Bain; Merlin G Butler; Olga Ilkayeva; Michael Muehlbauer; Andrea M Haqq; Michael Freemark
Journal:  Clin Endocrinol (Oxf)       Date:  2015-04-01       Impact factor: 3.478

4.  The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index.

Authors:  Andrea M Haqq; Michael J Muehlbauer; Christopher B Newgard; Steven Grambow; Michael Freemark
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

5.  Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.

Authors:  Alysa A Tennese; Rachel Wevrick
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

6.  A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome.

Authors:  J L Miller; C H Lynn; J Shuster; D J Driscoll
Journal:  J Hum Nutr Diet       Date:  2012-10-18       Impact factor: 3.089

7.  Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome.

Authors:  Pinar Gumus Balikcioglu; Metin Balikcioglu; Michael J Muehlbauer; Jonathan Q Purnell; David Broadhurst; Michael Freemark; Andrea M Haqq
Journal:  J Clin Endocrinol Metab       Date:  2015-08-10       Impact factor: 5.958

8.  Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.

Authors:  Jennifer L Miller; Tiffany D Linville; Elisabeth M Dykens
Journal:  J Pediatr Endocrinol Metab       Date:  2014-01       Impact factor: 1.634

Review 9.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

10.  Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development.

Authors:  Andrea M Haqq; Steven C Grambow; Michael Muehlbauer; Christopher B Newgard; Laura P Svetkey; Aaron L Carrel; Jack A Yanovski; Jonathan Q Purnell; Michael Freemark
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.